Heidelberg Pharma AG Cash Flow Conversion Efficiency
Heidelberg Pharma AG cash flow conversion efficiency. Based on the latest financial reports, Heidelberg Pharma AG (HPHA) has a cash flow conversion efficiency ratio of -0.299x as of May 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-5.53 Million ≈ $-6.46 Million USD) by net assets (€18.52 Million ≈ $21.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Heidelberg Pharma AG (2016–2024)
Cash flow conversion efficiency of Heidelberg Pharma AG from 2016 to 2024. This chart illustrates how Heidelberg Pharma AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Heidelberg Pharma AG stock price for real-time trading data and today's change.
Heidelberg Pharma AG Cash Flow Conversion Ratio Explained
Heidelberg Pharma AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Heidelberg Pharma AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Heidelberg Pharma AG ranked by their cash flow conversion efficiency. Also see market value of Heidelberg Pharma AG for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tribeca Global Natural Resources Ltd
AU:TGF
|
0.040x |
|
Stellar Resources Ltd
AU:SRZ
|
-0.353x |
|
Hennessy Capital Investment Corp. VII Unit
NASDAQ:HVIIU
|
-0.003x |
|
Soquicom
SN:SOQUICOM
|
-0.106x |
|
CSU Digital S.A.
SA:CSUD3
|
-0.626x |
|
Bank Negara Indonesia Tbk
JK:BBNI
|
0.385x |
|
OCK Group Bhd
KLSE:0172
|
-0.030x |
|
GnBS Engineering Co. Ltd.
KQ:382800
|
0.162x |
Annual Cash Flow Conversion Efficiency for Heidelberg Pharma AG (2016–2024)
The table below shows the annual cash flow conversion efficiency of Heidelberg Pharma AG from 2016 to 2024. Review cash generation quality of Heidelberg Pharma AG to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | €30.87 Million ≈ $36.09 Million |
€-29.59 Million ≈ $-34.59 Million |
-0.959x | -40.46% |
| 2023-11-30 | €49.34 Million ≈ $57.68 Million |
€-33.67 Million ≈ $-39.37 Million |
-0.682x | -413.10% |
| 2022-11-30 | €66.64 Million ≈ $77.91 Million |
€-8.86 Million ≈ $-10.36 Million |
-0.133x | +96.65% |
| 2021-11-30 | €6.70 Million ≈ $7.83 Million |
€-26.61 Million ≈ $-31.11 Million |
-3.973x | -185.96% |
| 2020-11-30 | €12.88 Million ≈ $15.06 Million |
€-17.89 Million ≈ $-20.92 Million |
-1.389x | -164.54% |
| 2019-11-30 | €16.29 Million ≈ $19.05 Million |
€-8.56 Million ≈ $-10.00 Million |
-0.525x | -36.17% |
| 2018-11-30 | €25.89 Million ≈ $30.26 Million |
€-9.98 Million ≈ $-11.67 Million |
-0.386x | -79.83% |
| 2017-11-30 | €37.02 Million ≈ $43.28 Million |
€-7.94 Million ≈ $-9.28 Million |
-0.214x | +67.98% |
| 2016-11-30 | €9.76 Million ≈ $11.41 Million |
€-6.53 Million ≈ $-7.64 Million |
-0.670x | -- |
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amaniti… Read more